REMS Daily Archives
An Integrated Risk Evaluation and Mitigation Strategy for Fentanyl Buccal Tablet (FENTORA®) and Oral Transmucosal Fentanyl Citrate (ACTIQ®)
Dec 7, 2011In this supplement, we present the background to the REMS program, a brief review of BTP along with the clinical data supporting the use of FENTORA and ACTIQ for BTP in appropriate opioid-tolerant patients, and an overview of the recently approved REMS for FENTORA and ACTIQ.
Download to read this article in PDF document:
Previous page: REMS Daily Next page: REMS Events
